Survival outcome of neoadjuvant endocrine therapy plus trastuzumab and pertuzumab (ET plus T plus P) vs. de-escalated chemotherapy (CT) plus T plus P in hormone receptor positive (HR+)/HER2+early breast cancer (EBC): WSG-TP-II trial

被引：0
|
作者：
Gluz, O. [1 ]
Nitz, U. A. [2 ]
Christgen, M. [3 ]
Kummel, S. [4 ]
Holtschmidt, J. [5 ]
Schumacher, J. [6 ]
Hartkopf, A. D. [7 ]
Luedtke-Heckenkamp, K. [8 ]
Just, M. [9 ]
von Schumann, R. [10 ]
Polata, S. [11 ]
Schinkoethe, T. [12 ]
Graeser-Mayer, M. K. [13 ]
Kates, R. E. [14 ]
Wuerstlein, R. [15 ]
Kreipe, H. [3 ]
Harbeck, N. [16 ]
机构：
[1] Evangeliches Krankenhaus Bethesda Klin, Breast Ctr, Monchengladbach, Germany
[2] West German Study Grp, Senol, Monchengladbach, Germany
[3] MHH, Pathol, Hannover, Germany
[4] Kliniken Essen Mitte Evang Huyssens Stiftung, Breast Unit, Essen, Germany
[5] St Elisabeth Clin Hohenlind, Breast Ctr, Cologne, Germany
[6] Palleos GmbH, Stat, Wiesbaden, Germany
[7] Univ Hosp Tubingen, Ctr Womens Hlth, Tubingen, Germany
[8] Niels Stensen Kliniken GmbH, Franziskus Hosp Harderberg, Oncol Dept, Georgsmarienhutte, Germany
[9] Onkol Schwerpunkt Praxis, Oncol, Greifswald, Germany
[10] Johanniter Bethesda Moenchengladbach, Breast Ctr Niederrhein, Monchengladbach, Germany
[11] Oncol Ctr Spandau, Oncol, Berlin, Germany
[12] LMU Klinikum Univ Munchen, Breast Ctr, Munich, Germany
[13] Westdeutsch Studiengrp GmbH, Senol, Monchengladbach, Germany
[14] Westdeutsch Studiengrp GmbH, Breast Ctr Dept, Monchengladbach, Germany
[15] LMU Klinikum Univ Munchen, Breast Ctr Dept, Munich, Germany
[16] LMU Univ Hosp, Dept Obstet & Gynecol, Breast Ctr, Munich, Germany
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.2255
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA17
引用
收藏
页码：1210 / 1210
页数：1
相关论文
共 50 条
  • [31] De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR1/HER21 Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial
    Harbeck, Nadia
    Nitz, Ulrike A.
    Christgen, Matthias
    Kuemmel, Sherko
    Braun, Michael
    Schumacher, Claudia
    Potenberg, Jochem
    Tio, Joke
    Aktas, Bahriye
    Forstbauer, Helmut
    Grischke, Eva-Maria
    Scheffen, Iris
    Malter, Wolfram
    von Schumann, Raquel
    Just, Marianne
    zu Eulenburg, Christine
    Biehl, Claudia
    Kolberg-Liedtke, Cornelia
    Deurloo, Regula
    de Haas, Sanne
    Jozwiak, Katarzyna
    Hauptmann, Michael
    Kates, Ronald
    Graeser, Monika
    Wuerstlein, Rachel
    Kreipe, Hans H.
    Gluz, Oleg
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (22) : 3796 - +
  • [32] Impact of RNA expression signatures and tumour infiltrating lymphocytes (TILs) for pathological complete response (pCR) and survival after 12 week de-escalated neoadjuvant pertuzumab plus trastuzumab ± paclitaxel in the WSG-HER2+/HR- ADAPT trial
    Graeser, M.
    Gluz, O.
    Biehl, C.
    Ulbrich-Gebauer, D.
    Palatty, J.
    Christgen, M.
    Kuemmel, S.
    Grischke, E-M.
    Augustin, D.
    Braun, M.
    Potenberg, J.
    Wuerstlein, R.
    Eulenburg, C.
    Kates, R.
    Kolberg-Liedtke, C.
    Feuerhake, F.
    Kreipe, H.
    Nitz, U.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S48 - S48
  • [33] Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
    Loi, Sherene
    Johnston, Stephen R. D.
    Arteaga, Carlos L.
    Graff, Stephanie L.
    Chandarlapaty, Sarat
    Goetz, Matthew P.
    Desmedt, Christine
    Sasano, Hironobu
    Liu, Deli
    Rodrik-Outmezguine, Vanessa
    Sireci, Anthony
    Sandoval, Cynthia
    Won, Helen H.
    Litchfield, Lacey M.
    Turner, Nicholas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA507 - LBA507
  • [34] Prognostic Utility of ctDNA Detection in The monarchE Trial of Adjuvant Abemaciclib Plus Endocrine therapy (ET) in HR+, HER2-, Node-positive, High-risk Early Breast Cancer (EBC)
    Loi, S.
    Johnston, S.
    Arteaga, C.
    Graff, S.
    Chandarlapaty, S.
    Goetz, M.
    Desmedt, C.
    Sasano, H.
    Liu, D.
    Rodrik-Outmezguine, V.
    Sireci, A.
    Sandoval, C.
    Won, H.
    Litchfield, L.
    Turner, N.
    BREAST, 2025, 80
  • [35] Correlation of peripheral T cell receptor repertoire with response to neoadjuvant chemotherapy plus trastuzumab in early-stage HER2-positive breast cancer.
    Wang, Wenna
    Ma, Fei
    Chen, Wenting
    Fan, Ying
    Yi, Zongbi
    Xiong, Dengkun
    Wang, Yuqi
    Guan, Yan-Fang
    Guan, Xiuwen
    Xia, Xuefeng
    Yang, Ling
    Yi, Xin
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] COST-EFFECTIVENESS OF COMBINATION PERTUZUMAB plus TRASTUZUMAB VS TRASTUZUMAB IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2POSITIVE EARLY BREAST CANCER (HER2+EBC) IN THE CZECH REPUBLIC
    Motylova, S.
    Dolezel, J.
    Novak, J.
    Pour, M.
    Krihova, K.
    Skalicky, D.
    VALUE IN HEALTH, 2023, 26 (12) : S351 - S351
  • [37] Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy (ET)-naive, hormone receptor-positive (HR plus ) advanced breast cancer (FALCON)
    Robertson, J.
    Shao, Z.
    Noguchi, S.
    Singh, S.
    Subramaniam, S.
    Ellis, M. J.
    ANNALS OF ONCOLOGY, 2023, 34 : S339 - S340
  • [38] Hormone receptor positive (HR plus )/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer: Sequencing of chemotherapy and endocrine therapy
    Engel-Nitz, Nicole M.
    Hao, Yanni
    Rogerio, Jaqueline Willemann
    Turnbull, James D.
    Rey, Gabriel Gomez
    Sullivan, Jane
    Rossof, Arthur H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [39] NSABP FB-7: A phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N plus T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer
    Jacobs, S. A.
    Robidoux, A.
    Garcia, J. M. P.
    Abraham, J.
    La Verde, N.
    Orcutt, J. M.
    Cazzaniga, M. E.
    Calvo, L.
    Aguirre, E.
    Buyse, M.
    Pogue-Geile, K. L.
    Srinivasan, A.
    Song, N.
    Balousek, A. D.
    Wolmark, N.
    CANCER RESEARCH, 2016, 76
  • [40] Efficacy and safety of the combination of pertuzumab (P) plus trastuzumab (T) plus docetaxel (D) for HER-2 positive metastatic breast cancer (MBC) in pretreated patients (pts) with trastuzumab in the neoiadjuvant setting: A real-life study.
    Ricciardi, Giuseppina
    Ficorella, Corrado
    Iezzi, Laura
    Marchetti, Paolo
    Pizzuti, Laura
    Prestifilippo, Angela
    Schifano, Silvia
    Maimone, Sergio
    Adamo, Vincenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345